Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment
Objective: To assess TDIS and global AIMS measures change trajectories using data from KINECT-4, an open-label 52-week trial assessing valbenazine in TD [1] Background: AIMS…Burden and management of tardive dyskinesia (TD): a cross-sectional international survey study to assess the perceptions and experiences of patients with TD
Objective: To assess patient perceptions of and experiences with TD and its impact on their daily functioning and quality of life (QoL). Background: There is…Crushing valbenazine capsule contents for potential addition to soft foods or administration via G tube
Objective: To evaluate the suitability of mixing crushed contents from valbenazine capsules with soft foods/liquids or adding them to water for delivery through a gastrostomy…Belly Dance Dyskinesia, a manifestation of B12 deficiency and hyperhomocysteinuria in MTHFR gene mutation. Videographic record of a case.
Objective: We present a case of probable Belly Dance Dyskinesia (BDD) secondary to vitamin B12 deficiency. Background: BDD is a rare movement disorder (considered a…The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit
Objective: To assess the real-world utilization of deutetrabenazine (DTBZ) for the treatment of tardive dyskinesia (TD) or chorea associated with Huntington disease (HD) initiated by…Levosulpiride and Movement Disorders–A Growing Concern
Objective: To describe a series of patients with levosulpiride (LVS) induced movement disorders (LIM) evaluated at a single movement disorder center, the All India Institute…A STUDY OF CLINICAL SPECTRUM, RISK FACTORS AND OUTCOME OF DRUG-INDUCED MOVEMENT DISORDERS
Objective: We aimed to characterize the spectrum of DIMDs, and the culprit agents commonly encountered in the movement disorder clinic. We also set out to…Novel Antipsychotics and Risk of Drug-Induced Movement Disorders and Tardive Syndromes
Objective: To review evidence on the risk of drug-induced movement disorders (DIMDs) with newer antipsychotic (AP) drugs. Background: DIMDs, both acute/subacute “extrapyramidal symptoms” and chronic…Trending the educational needs of US physicians related to managing patients with tardive dyskinesia
Objective: This study sought to understand evolving continuing medical education (CME) needs of US physicians managing patients with tardive dyskinesia (TD) by assessing the knowledge, practice, and barriers at three timepoints…Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »